Changes to fibrinolysis in patients with systemic lupus erythematosus are associated with endothelial cell damage and inflammation, but not antiphospholipid antibodies
We investigated whether changes to fibrinolysis were associated with other manifestations of systemic lupus erythematosus (SLE), including antiphospholipid (APL) antibody status, endothelial damage, and inflammation. Ninety-four patients (36 SLE patients, 58 healthy controls) were recruited from Tas...
Gespeichert in:
| Veröffentlicht in: | Blood coagulation & fibrinolysis 2016-12, Vol.27 (8), p.870-875 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 875 |
|---|---|
| container_issue | 8 |
| container_start_page | 870 |
| container_title | Blood coagulation & fibrinolysis |
| container_volume | 27 |
| creator | Dhillon, Parvinderjit K Khalafallah, Alhossain A Adams, Murray J |
| description | We investigated whether changes to fibrinolysis were associated with other manifestations of systemic lupus erythematosus (SLE), including antiphospholipid (APL) antibody status, endothelial damage, and inflammation. Ninety-four patients (36 SLE patients, 58 healthy controls) were recruited from Tasmania, Australia. Circulating levels of plasminogen, α2-antiplasmin, tissue-type plasminogen activator, plasminogen activator inhibitor-1, and thrombin-activatable fibrinolysis inhibitor (TAFI) were measured, as well as APL antibodies (including lupus anticoagulant, anticardiolipin, and antibeta-2 glycoprotein-1 antibodies), soluble E-selectin, and interleukin-6. Whereas there was a significant decrease in plasminogen (patient vs. control; median) (210 vs. 444 ng/ml; P |
| doi_str_mv | 10.1097/MBC.0000000000000504 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1826681963</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1826681963</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3564-dab85ed603db7d635d14b0021b5ab468b4e3d3fda9f111b998082402a33959903</originalsourceid><addsrcrecordid>eNp9kc1u1TAQhS1ERS-FN0DISxakteM4iZdwxZ9UxAbWkR1PGoNjB4-jq_tEfU1cbkGIRUeyRmN_54ylQ8gLzi45U93V57f7S_ZvSdY8IjvedKKSnRCPyY4p2VWyFvKcPEX8XhjR9N0Tcl53vO16qXbkdj_rcANIc6STM8mF6I_okLpAV50dhIz04PJM8YgZFjdSv60bUkjHPMOic8Qy6QRUI8bR6Qz2JIBgY0G8056O4D21etE3hQu2uE9eL0XtYnhNzZZpiLm8ZLfOEcvxbnX294WJ1gE-I2eT9gjP7_sF-fb-3df9x-r6y4dP-zfX1Shk21RWm16CbZmwprOtkJY3hrGaG6lN0_amAWHFZLWaOOdGqZ71dcNqLYSSSjFxQV6dfNcUf26AeVgc3v1eB4gbDryv27bnqhUFbU7omCJigmlYk1t0Og6cDXcRDSWi4f-Iiuzl_YbNLGD_iv5kUoD-BByiz5Dwh98OkIYZtM_zw96_ADfloac</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1826681963</pqid></control><display><type>article</type><title>Changes to fibrinolysis in patients with systemic lupus erythematosus are associated with endothelial cell damage and inflammation, but not antiphospholipid antibodies</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Dhillon, Parvinderjit K ; Khalafallah, Alhossain A ; Adams, Murray J</creator><creatorcontrib>Dhillon, Parvinderjit K ; Khalafallah, Alhossain A ; Adams, Murray J</creatorcontrib><description>We investigated whether changes to fibrinolysis were associated with other manifestations of systemic lupus erythematosus (SLE), including antiphospholipid (APL) antibody status, endothelial damage, and inflammation. Ninety-four patients (36 SLE patients, 58 healthy controls) were recruited from Tasmania, Australia. Circulating levels of plasminogen, α2-antiplasmin, tissue-type plasminogen activator, plasminogen activator inhibitor-1, and thrombin-activatable fibrinolysis inhibitor (TAFI) were measured, as well as APL antibodies (including lupus anticoagulant, anticardiolipin, and antibeta-2 glycoprotein-1 antibodies), soluble E-selectin, and interleukin-6. Whereas there was a significant decrease in plasminogen (patient vs. control; median) (210 vs. 444 ng/ml; P < 0.0001) and increase in α2-antiplasmin (0.53 vs. 0.09 μg/ml; P = 0.0007), there was increased t-PA (0.65 vs. 0.40 ng/ml; P = 0.0001) and decreased TAFI (8.8 vs. 10.0 ng/ml; P = 0.002) in SLE patients compared to healthy controls. Plasminogen was significantly associated with α2-antiplasmin (rho = −0.563, P < 0.001); TAFI (rho = 0.410, P = 0.011); soluble E-selectin (rho = 0.531, P = 0.001); and interleukin-6 (rho = 0.489, P = 0.002) in SLE patients; however, APL antibody status was not associated with any of the markers measured. This study has demonstrated that fibrinolysis is significantly altered in patients with SLE compared to controls, and associated with endothelial cell damage and inflammation, but not APL antibody status.</description><identifier>ISSN: 0957-5235</identifier><identifier>EISSN: 1473-5733</identifier><identifier>DOI: 10.1097/MBC.0000000000000504</identifier><identifier>PMID: 27167859</identifier><language>eng</language><publisher>England: Copyright YEAR Wolters Kluwer Health, Inc. All rights reserved</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antibodies, Antiphospholipid - metabolism ; Female ; Fibrinolysis ; Humans ; Inflammation - complications ; Lupus Erythematosus, Systemic - complications ; Male ; Middle Aged ; Young Adult</subject><ispartof>Blood coagulation & fibrinolysis, 2016-12, Vol.27 (8), p.870-875</ispartof><rights>Copyright © 2016 YEAR Wolters Kluwer Health, Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3564-dab85ed603db7d635d14b0021b5ab468b4e3d3fda9f111b998082402a33959903</citedby><cites>FETCH-LOGICAL-c3564-dab85ed603db7d635d14b0021b5ab468b4e3d3fda9f111b998082402a33959903</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27167859$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dhillon, Parvinderjit K</creatorcontrib><creatorcontrib>Khalafallah, Alhossain A</creatorcontrib><creatorcontrib>Adams, Murray J</creatorcontrib><title>Changes to fibrinolysis in patients with systemic lupus erythematosus are associated with endothelial cell damage and inflammation, but not antiphospholipid antibodies</title><title>Blood coagulation & fibrinolysis</title><addtitle>Blood Coagul Fibrinolysis</addtitle><description>We investigated whether changes to fibrinolysis were associated with other manifestations of systemic lupus erythematosus (SLE), including antiphospholipid (APL) antibody status, endothelial damage, and inflammation. Ninety-four patients (36 SLE patients, 58 healthy controls) were recruited from Tasmania, Australia. Circulating levels of plasminogen, α2-antiplasmin, tissue-type plasminogen activator, plasminogen activator inhibitor-1, and thrombin-activatable fibrinolysis inhibitor (TAFI) were measured, as well as APL antibodies (including lupus anticoagulant, anticardiolipin, and antibeta-2 glycoprotein-1 antibodies), soluble E-selectin, and interleukin-6. Whereas there was a significant decrease in plasminogen (patient vs. control; median) (210 vs. 444 ng/ml; P < 0.0001) and increase in α2-antiplasmin (0.53 vs. 0.09 μg/ml; P = 0.0007), there was increased t-PA (0.65 vs. 0.40 ng/ml; P = 0.0001) and decreased TAFI (8.8 vs. 10.0 ng/ml; P = 0.002) in SLE patients compared to healthy controls. Plasminogen was significantly associated with α2-antiplasmin (rho = −0.563, P < 0.001); TAFI (rho = 0.410, P = 0.011); soluble E-selectin (rho = 0.531, P = 0.001); and interleukin-6 (rho = 0.489, P = 0.002) in SLE patients; however, APL antibody status was not associated with any of the markers measured. This study has demonstrated that fibrinolysis is significantly altered in patients with SLE compared to controls, and associated with endothelial cell damage and inflammation, but not APL antibody status.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies, Antiphospholipid - metabolism</subject><subject>Female</subject><subject>Fibrinolysis</subject><subject>Humans</subject><subject>Inflammation - complications</subject><subject>Lupus Erythematosus, Systemic - complications</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Young Adult</subject><issn>0957-5235</issn><issn>1473-5733</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1u1TAQhS1ERS-FN0DISxakteM4iZdwxZ9UxAbWkR1PGoNjB4-jq_tEfU1cbkGIRUeyRmN_54ylQ8gLzi45U93V57f7S_ZvSdY8IjvedKKSnRCPyY4p2VWyFvKcPEX8XhjR9N0Tcl53vO16qXbkdj_rcANIc6STM8mF6I_okLpAV50dhIz04PJM8YgZFjdSv60bUkjHPMOic8Qy6QRUI8bR6Qz2JIBgY0G8056O4D21etE3hQu2uE9eL0XtYnhNzZZpiLm8ZLfOEcvxbnX294WJ1gE-I2eT9gjP7_sF-fb-3df9x-r6y4dP-zfX1Shk21RWm16CbZmwprOtkJY3hrGaG6lN0_amAWHFZLWaOOdGqZ71dcNqLYSSSjFxQV6dfNcUf26AeVgc3v1eB4gbDryv27bnqhUFbU7omCJigmlYk1t0Og6cDXcRDSWi4f-Iiuzl_YbNLGD_iv5kUoD-BByiz5Dwh98OkIYZtM_zw96_ADfloac</recordid><startdate>20161201</startdate><enddate>20161201</enddate><creator>Dhillon, Parvinderjit K</creator><creator>Khalafallah, Alhossain A</creator><creator>Adams, Murray J</creator><general>Copyright YEAR Wolters Kluwer Health, Inc. All rights reserved</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20161201</creationdate><title>Changes to fibrinolysis in patients with systemic lupus erythematosus are associated with endothelial cell damage and inflammation, but not antiphospholipid antibodies</title><author>Dhillon, Parvinderjit K ; Khalafallah, Alhossain A ; Adams, Murray J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3564-dab85ed603db7d635d14b0021b5ab468b4e3d3fda9f111b998082402a33959903</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies, Antiphospholipid - metabolism</topic><topic>Female</topic><topic>Fibrinolysis</topic><topic>Humans</topic><topic>Inflammation - complications</topic><topic>Lupus Erythematosus, Systemic - complications</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dhillon, Parvinderjit K</creatorcontrib><creatorcontrib>Khalafallah, Alhossain A</creatorcontrib><creatorcontrib>Adams, Murray J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Blood coagulation & fibrinolysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dhillon, Parvinderjit K</au><au>Khalafallah, Alhossain A</au><au>Adams, Murray J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Changes to fibrinolysis in patients with systemic lupus erythematosus are associated with endothelial cell damage and inflammation, but not antiphospholipid antibodies</atitle><jtitle>Blood coagulation & fibrinolysis</jtitle><addtitle>Blood Coagul Fibrinolysis</addtitle><date>2016-12-01</date><risdate>2016</risdate><volume>27</volume><issue>8</issue><spage>870</spage><epage>875</epage><pages>870-875</pages><issn>0957-5235</issn><eissn>1473-5733</eissn><abstract>We investigated whether changes to fibrinolysis were associated with other manifestations of systemic lupus erythematosus (SLE), including antiphospholipid (APL) antibody status, endothelial damage, and inflammation. Ninety-four patients (36 SLE patients, 58 healthy controls) were recruited from Tasmania, Australia. Circulating levels of plasminogen, α2-antiplasmin, tissue-type plasminogen activator, plasminogen activator inhibitor-1, and thrombin-activatable fibrinolysis inhibitor (TAFI) were measured, as well as APL antibodies (including lupus anticoagulant, anticardiolipin, and antibeta-2 glycoprotein-1 antibodies), soluble E-selectin, and interleukin-6. Whereas there was a significant decrease in plasminogen (patient vs. control; median) (210 vs. 444 ng/ml; P < 0.0001) and increase in α2-antiplasmin (0.53 vs. 0.09 μg/ml; P = 0.0007), there was increased t-PA (0.65 vs. 0.40 ng/ml; P = 0.0001) and decreased TAFI (8.8 vs. 10.0 ng/ml; P = 0.002) in SLE patients compared to healthy controls. Plasminogen was significantly associated with α2-antiplasmin (rho = −0.563, P < 0.001); TAFI (rho = 0.410, P = 0.011); soluble E-selectin (rho = 0.531, P = 0.001); and interleukin-6 (rho = 0.489, P = 0.002) in SLE patients; however, APL antibody status was not associated with any of the markers measured. This study has demonstrated that fibrinolysis is significantly altered in patients with SLE compared to controls, and associated with endothelial cell damage and inflammation, but not APL antibody status.</abstract><cop>England</cop><pub>Copyright YEAR Wolters Kluwer Health, Inc. All rights reserved</pub><pmid>27167859</pmid><doi>10.1097/MBC.0000000000000504</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0957-5235 |
| ispartof | Blood coagulation & fibrinolysis, 2016-12, Vol.27 (8), p.870-875 |
| issn | 0957-5235 1473-5733 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1826681963 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adult Aged Aged, 80 and over Antibodies, Antiphospholipid - metabolism Female Fibrinolysis Humans Inflammation - complications Lupus Erythematosus, Systemic - complications Male Middle Aged Young Adult |
| title | Changes to fibrinolysis in patients with systemic lupus erythematosus are associated with endothelial cell damage and inflammation, but not antiphospholipid antibodies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T13%3A11%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Changes%20to%20fibrinolysis%20in%20patients%20with%20systemic%20lupus%20erythematosus%20are%20associated%20with%20endothelial%20cell%20damage%20and%20inflammation,%20but%20not%20antiphospholipid%20antibodies&rft.jtitle=Blood%20coagulation%20&%20fibrinolysis&rft.au=Dhillon,%20Parvinderjit%20K&rft.date=2016-12-01&rft.volume=27&rft.issue=8&rft.spage=870&rft.epage=875&rft.pages=870-875&rft.issn=0957-5235&rft.eissn=1473-5733&rft_id=info:doi/10.1097/MBC.0000000000000504&rft_dat=%3Cproquest_cross%3E1826681963%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1826681963&rft_id=info:pmid/27167859&rfr_iscdi=true |